Concomitantly, spike-specific T-cell response was evaluated and scored positive in 69% of RA patients vs. 100% of HCWs with significantly lower levels in those under a biological therapy compared to HCWs, particularly in patients under CTLA-4-inhibitors or IL-6-inhibitors. The gene discussed is CTLA4; the disease is rheumatoid arthritis.